CG Oncology, Inc. Common stock
$59.56
The Read: CG Oncology's stock has shown high volatility around FDA-related catalysts, rallying about 18% on positive rolling BLA updates in February 2026, gaining 6% with strong Phase 2 results and BLA progress in May, but then dropping sharply about 35% in early June 2026 due to investor disappointment over pre-PDUFA commercial stockpiling and rising expenses despite meeting earnings estimates.
Price
Overlays
Panel
CGON
Hover to view data
No Data